Biocept, Clarient Partner to Commercialize CTC Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GE Healthcare's Clarient will commercialize Biocept's blood test for circulating tumor cells under a deal announced today.

Clarient will market and sell the OncoCEE-BR test to community hospitals, pathologists, and medical oncologists. Biocept will run the test in its CLIA laboratory and Clarient Pathology Services will analyze the results.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.